WAY-200

WAY-200 is a small molecule inhibitor of protein tyrosine phosphatase 1B (PTP1B), a key negative regulator of insulin and leptin signaling. Developed by Wyeth (now Pfizer), the compound was investigated as a potential therapeutic for type 2 diabetes and obesity. By inhibiting PTP1B, WAY-200 was intended to enhance insulin receptor phosphorylation and downstream signaling, thereby improving glucose homeostasis and insulin sensitivity. Despite the therapeutic potential of PTP1B as a target, the development of WAY-200 was discontinued during early-stage research, a common outcome for many early PTP1B inhibitors due to challenges in achieving optimal pharmacological properties and selectivity over other phosphatases.